Company: NIVFW
Filing Date: 2025-10-10
Form Type: F-1/A
Source: 0001213900-25-098135
Chunk: 271

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-10
Form: F-1/A
Chunk 271
---
 price less than the fixed conversion price then in effect. The holder of the Note may convert any portion of the outstanding portion of the Note into validly issued, fully paid and non-assessable Class A Shares at the conversion price. No fractional Class A Shares are issuable upon any such conversion. If the issuance would result in the issuance of a fraction of a Class A Share, the Company shall round such fraction of a Class A Share up to the nearest whole share. The Fourth Tranche Note is included as Exhibit 4.1 in the Form 6-K filed on July 16, 2025, which is incorporated herein by reference. Between November 7, 2024 and the date of this prospectus, the Company received gross proceeds of $7,850,000 and issued an aggregate of 573,837 Class A Ordinary Shares (on a post Reverse Stock Splits basis) to the Buyers. The Company may receive up to approximately $18,540,961 in additional net proceeds from the 2024 Debt Financing if all remaining Additional Notes in the aggregate principal amount of $3,150,000 (together with the Fourth Tranche Note and Fifth Tranche Note,the “Remaining Additional Notes”) issuable pursuant to the Securities Purchase Agreement are sold and (ii) the Series A Warrants are increased by 10,157,580 assuming that (A) all Remaining Additional Notes are sold and (B) an Additional Share Price is equal to $1.3513 and (iii) all of the Warrants are exercised in full, based on the following assumptions (x) approximately $23,909,021 in net proceeds are received from the exercise of the Series A Warrants, assuming that the Series A Warrants are exercised in full at an exercise price of $1.8258 and the number of Ordinary Shares issuable upon exercise of the Series A Warrants equals 13,095,093, (y) approximately $1,485 in net proceeds are received from the exercise of the Series B Warrants, assuming that the Series B Warrants are exercised in full at an exercise price of $0.020 per share, and (z) approximately $3,005,784 in net proceeds are received from the exercise of the Exchange Warrants, assuming that the Exchange Warrants are exercised in full at an exercise price of $1.8258. The foregoing is subject to adjustment as set forth in the respective Notes and Warrants, as applicable. II-3 White Lion Equity Line of Credit